Indobufen-based dual antiplatelet therapy in patients with multivessel coronary disease undergoing drug-eluting stent implantation insight from the OPTION trial
Authors' conclusion
In patients with MVD, indobufen plus clopidogrel DAPT compared to aspirin plus clopidogrel DAPT could reduce the risk of bleeding events while preserving ischemic protection during both the first and second 6 months post-PCI.
Study context
- Population
- Patients undergoing DES implantation (PCI) in the OPTION trial, with and without multivessel coronary disease (MVD)
- Comparison
- Indobufen-based dual antiplatelet therapy (DAPT) vs conventional DAPT
- Primary endpoint
- Ischemic and bleeding events
- Follow-up
- First and second 6 months post-PCI (landmarks at 6 months and 1 year)
Methodological detailssubgroup analysis by MVD, landmark analysis at 6 months
- Subgroup analysis by MVD
- Landmark analysis at 6 months
Primary result
As reported in the abstract
first and second 6 months post-PCI
- Ischemic events similar with indobufen-based vs conventional DAPT, with or without MVD, in the first and second 6 months
- First 6 months: indobufen-based DAPT reduced bleeding events consistently with and without MVD
- Second 6 months: indobufen-based DAPT reduced bleeding events with MVD but not without MVD
Further findings
MVD vs no MVD (prognosis)
- Patients with MVD at higher risk of net adverse clinical events and ischemic events than those without MVD
Original publication
Indobufen-based dual antiplatelet therapy in patients with multivessel coronary disease undergoing drug-eluting stent implantation insight from the OPTION trial. Am Heart J. Published 20 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →